Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 93

1.

Epidemiology of children with acquired immune deficiency syndrome (stage 3): A referral hospital-based study in Iran.

Movahedi Z, Mahmoudi S, Pourakbari B, Keshavarz Valian N, Sabouni F, Ramezani A, Bahador A, Mamishi S.

J Med Virol. 2016 Jan;88(1):64-8. doi: 10.1002/jmv.24294.

PMID:
26512710
2.

Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART.

Lapadula G, Chatenoud L, Gori A, Castelli F, Di Giambenedetto S, Fabbiani M, Maggiolo F, Focà E, Ladisa N, Sighinolfi L, Di Pietro M, Pan A, Torti C; Italian MASTER Cohort.

PLoS One. 2015 May 28;10(5):e0124741. doi: 10.1371/journal.pone.0124741. eCollection 2015.

3.

Impact of hepatitis B virus infection on HIV response to antiretroviral therapy in a Chinese antiretroviral therapy center.

Yang R, Gui X, Xiong Y, Gao SC, Yan Y.

Int J Infect Dis. 2014 Nov;28:29-34. doi: 10.1016/j.ijid.2014.07.018. Epub 2014 Sep 16.

4.

[GeSIDA/National AIDS Plan: Consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2014)].

Panel de expertos de GeSIDA; Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2014 Aug-Sep;32(7):446.e1-42. doi: 10.1016/j.eimc.2014.02.019. Epub 2014 Jun 19. Spanish.

PMID:
24953253
5.

Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.

Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, Wang L, Ou SS, Anderson M, McCauley M, Gamble T, Kumarasamy N, Hakim JG, Kumwenda J, Pilotto JH, Godbole SV, Chariyalertsak S, de Melo MG, Mayer KH, Eshleman SH, Piwowar-Manning E, Makhema J, Mills LA, Panchia R, Sanne I, Gallant J, Hoffman I, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Havlir D, Cohen MS; HPTN 052-ACTG Study Team.

Lancet Infect Dis. 2014 Apr;14(4):281-90. doi: 10.1016/S1473-3099(13)70692-3. Epub 2014 Mar 4. Erratum in: Lancet Infect Dis. 2014 Apr;14(4):269.

6.

Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe.

Zoufaly A, Cozzi-Lepri A, Reekie J, Kirk O, Lundgren J, Reiss P, Jevtovic D, Machala L, Zangerle R, Mocroft A, Van Lunzen J; EuroSIDA in EuroCoord.

PLoS One. 2014 Jan 31;9(1):e87160. doi: 10.1371/journal.pone.0087160. eCollection 2014.

8.

Executive summary of the Consensus Document of GeSIDA and Spanish Secretariat for the National Plan on AIDS on combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2013).

Panel of Experts of GESIDA and Spanish Secretariat for the National Plan on AIDS.

Enferm Infecc Microbiol Clin. 2013 Nov;31(9):604-13. doi: 10.1016/j.eimc.2013.04.010. Epub 2013 Oct 22.

PMID:
24156952
9.

Recombinant human soluble thrombomodulin is active against hemophagocytic lymphohistiocytosis associated with acquired immunodeficiency syndrome.

Chi S, Ikezoe T, Takeuchi A, Takaoka M, Yokoyama A.

Int J Hematol. 2013 Nov;98(5):615-9. doi: 10.1007/s12185-013-1450-5. Epub 2013 Oct 8.

PMID:
24101336
10.

Extrinsic and intrinsic coagulation pathway, fibrinogen serum level and platelet count in HIV positive patients.

Abdollahi A, Shoar N, Shoar S, Rasoulinejad M.

Acta Med Iran. 2013 Aug 7;51(7):472-6.

11.

Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC).

May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, D'Arminio Monforte A, Casabona J, Hogg RS, Mocroft A, Lampe FC, Dabis F, Fätkenheuer G, Sterling TR, del Amo J, Gill MJ, Crane HM, Saag MS, Guest J, Brodt HR, Sterne JA; Antiretroviral Cohort Collaboration.

Int J Epidemiol. 2014 Jun;43(3):691-702. doi: 10.1093/ije/dyt010. Epub 2013 Apr 18.

12.

Rate and predictors of non-AIDS events in a cohort of HIV-infected patients with a CD4 T cell count above 500 cells/mm³.

Lucero C, Torres B, León A, Calvo M, Leal L, Pérez I, Plana M, Arnedo M, Mallolas J, Gatell JM, García F.

AIDS Res Hum Retroviruses. 2013 Aug;29(8):1161-7. doi: 10.1089/AID.2012.0367. Epub 2013 Apr 18.

13.

All-cause mortality in hospitalized HIV-infected patients at an acute tertiary care hospital with a comprehensive outpatient HIV care program in New York City in the era of highly active antiretroviral therapy (HAART).

Kim JH, Psevdos G Jr, Gonzalez E, Singh S, Kilayko MC, Sharp V.

Infection. 2013 Apr;41(2):545-51. doi: 10.1007/s15010-012-0386-7. Epub 2012 Dec 21.

PMID:
23264096
14.

Long-term benefits of nevirapine-containing regimens: multicenter study with 506 patients, followed-up a median of 9 years.

Podzamczer D, Tiraboschi JM, Mallolas J, Curto J, Cárdenes MA, Casas E, Castro A, Echevarría S, Leal M, Lopez Bernaldo de Quirós JC, Moreno S, Puig T, Ribera E, Villalonga C, Gómez-Sirvent JL, García-Henarejos JA, Lopez-Aldeguer J, Barrufet P, Force L, Santos I, Sanz J.

Curr HIV Res. 2012 Sep;10(6):513-20.

PMID:
22716109
15.

Hepatitis C and HIV co-infection: new drugs in practice and in the pipeline.

Jennings CL, Sherman KE.

Curr HIV/AIDS Rep. 2012 Sep;9(3):231-7. doi: 10.1007/s11904-012-0122-z. Review.

16.

Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study.

Babiker AG, Emery S, Fätkenheuer G, Gordin FM, Grund B, Lundgren JD, Neaton JD, Pett SL, Phillips A, Touloumi G, Vjechaj MJ; INSIGHT START Study Group.

Clin Trials. 2013;10(1 Suppl):S5-S36. doi: 10.1177/1740774512440342. Epub 2012 Apr 30.

17.

Effect of liver fibrosis on long-term mortality in HIV/hepatitis C virus-coinfected individuals who are evaluated to receive interferon therapies in the highly active antiretroviral therapy era.

Sanmartin R, de Felipe E, Tor J, Sanvicens A, Barluenga E, Martinez E, Muga R, Jou A, Ojanguren I, López JJ, Clotet B, Tural C.

AIDS Res Hum Retroviruses. 2012 Oct;28(10):1235-43. Epub 2012 Apr 20.

PMID:
22443303
18.

Acute and chronic T cell dynamics in the livers of simian immunodeficiency virus-infected macaques.

Ahsan MH, Gill AF, Lackner AA, Veazey RS.

J Virol. 2012 May;86(9):5244-52. doi: 10.1128/JVI.07080-11. Epub 2012 Feb 29.

19.

Short communication: impact of hepatitis C viral clearance on CD4+ T-lymphocyte course in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.

Milazzo L, Foschi A, Mazzali C, Viola A, Ridolfo A, Galli M, Antinori S.

AIDS Res Hum Retroviruses. 2012 Sep;28(9):989-93. doi: 10.1089/AID.2011.0323. Epub 2012 Mar 13.

20.

Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort.

van Lelyveld SF, Gras L, Kesselring A, Zhang S, De Wolf F, Wensing AM, Hoepelman AI; ATHENA national observational cohort study.

AIDS. 2012 Feb 20;26(4):465-74. doi: 10.1097/QAD.0b013e32834f32f8.

PMID:
22112603
Items per page

Supplemental Content

Loading ...
Write to the Help Desk